# A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

> **NCT05796206** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** MIL62
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05796206
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-26
- **Primary completion:** 2026-02
- **Final completion:** 2026-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796206, "A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05796206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*